Navigation Links
Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
Date:11/12/2012

LA JOLLA, Calif., Nov. 12, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended September 30, 2012 on Monday, November 19, 2012, after the U.S. financial markets close.

Regulus will host a conference call and webcast on Monday, November 19, 2012 at 5:00 pm Eastern Standard Time to discuss its third quarter 2012 financial results and highlights. A live webcast of the call will be available online at www.regulusrx.com.  To access the telephone replay of the call, dial (855) 859-2056 (domestic) or (404) 537-3406 (international), passcode 52577487. The webcast and telephone replay will be archived on the company's website for two weeks following the call. 

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (NASDAQ: ALNY) and Isis Pharmaceuticals (NASDAQ: ISIS). Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
2. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
3. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
4. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
5. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
6. Valeritas Announces The Publication Of A Retrospective Analysis Of Patient-Reported Data On The V-Go In The Current Issue Of Endocrine Practice
7. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
8. 3SBio Inc. Announces Unaudited Third Quarter 2012 Results
9. Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November
10. FDAnews announces Fifth Annual Risk Management & Drug Safety Summit
11. Telik Announces Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... YORK , April 19, 2017 The Mobile ... to showcase a healthy CAGR during the forecast period ... type in the global digital mobile X-Ray devices market, which ... Mn in 2017, expanding at a CAGR of 7% over ... absolute $ opportunity of more than US$ 100 Mn in ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical ... patients in Nashville , Tennesse have ... Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. The ... provide long-term reflux control by restoring normal function to ... 65 million people in the United States ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... April 27, 2017 , ... ... On the heels of Thinksport’s award-winning sunscreen they’ve used the same scientific approach ... works! , Countless deodorants flood the aisles that contain harmful chemicals that should ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... 2017 North American CAREGiverSM of the Year for her extraordinary compassion and lifelong ... its 60,000 North American professional caregivers for the prestigious award each year – ...
(Date:4/27/2017)... , ... April 27, 2017 , ... Goodcents Deli Fresh ... in the Lincoln, Neb. area this year. , The first new location will ... second location will open at 84th and Northern Lights Drive this fall. And the ...
(Date:4/27/2017)... ... 27, 2017 , ... Are you investing in the safety of your friends ... during the summer. While most of us assume this type of accident will never ... few people are taking the time to learn how to respond effectively or prevent ...
(Date:4/26/2017)... MN (PRWEB) , ... April 26, 2017 , ... ... that improve supply management in hospitals, today announced it has completed a round ... Black Granite Capital LLC and its partners. Black Granite Capital is a growth ...
Breaking Medicine News(10 mins):